Cannabics Pharmaceuticals Announces Scientific Collaboration With A Leading CTC European Lab
TEL AVIV, Israel, May 3, 2017 /PRNewswire/ — Cannabics Pharmaceuticals Inc. (CNBX) today announced it has begun a scientific collaboration with a medical laboratory in Europe, a world leader in the field of CTC (circulating tumor cells) count and drug sensitivity tests for cancer patients.
The company wishes to provide patients with information regarding the effectiveness of both cannabinoid compounds and other therapies. The blood test results enables practitioners and patients to monitor the number of circulating tumor cells as an indication for cancer characteristics, treatment efficacy and and re-occurrence.
Dr. Eyal Ballan, Co-founder and CTO, said: “Many cancer patients are treated with cannabis, either in conjunction with chemotherapy or without. Our aim is to provide them with a lab test to help monitor the effectiveness of the treatment, using a simple blood test.”
Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-K/A Report filed on March 15, 2017. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.